Browse
Submit Data
Databases
API
Help

Dataset Information

12 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Clinical study for detoxification and dispersal herbs combined with TACE in the treatment of unresectable liver metastasis of colorectal cancer and its correlation with exogenous microRNAs

ABSTRACT: Interventions: experimental group:detoxification and dispersal herbs combined with TACE ;control group:placebo (herb) combined with TACE Primary outcome(s): PFS Study Design: Parallel

DISEASE(S): Colorectal Cancer Liver Metastases

PROVIDER: 2686364 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Clinical study of pembrolizumab combined with DEB-TACE in unresectable MSI-H/dMMR colorectal cancer liver metastasis

Project description:Interventions: Experimental group:Pembrolizumab + DEB-TACE Primary outcome(s): objective response rate Study Design: Single arm

| 37109 | ecrin-mdr-crc

Efficacy evaluation and safety analysis of TACE combined with HIFU in the treatment of liver metastases unresectable colorectal cancer

Project description:Interventions: experimental group:TACE+HIFU;control group: TACE Primary outcome(s): ORR Study Design: Parallel

| 2697767 | ecrin-mdr-crc

The study of TACE combined with apatinib for unresectable liver metastasis after colorectal cancer surgery

Project description:Interventions: Case series:TACE combined with apatinib Primary outcome(s): time to progression Study Design: Non randomized control

| 2677541 | ecrin-mdr-crc

Phosphorylation of iRhom2 controls stimulated proteolytic shedding by the metalloprotease ADAM17/TACE

Project description:TACE (TNFa Converting Enzyme), is responsible for cleavage (‘shedding’) of membrane-tethered signaling molecules such as TNF of EGFR ligands. TACE interacts with iRhom2, which mediates the exit of TACE from the endoplasmic reticulum. In this study we analyze a new role for iRHOM2, where a fraction of the protein remains in the membrane and the phosphorylation of different residues in its cytoplasmatic tail is necessary for TACE shedding function.

2021-11-03 | PXD007763 | Pride

An open-label, single-arm, prospective study of TACE combined with apatinib for unresectable liver metastases from colorectal cancer

Project description:Interventions: Treatment group:TACE combined with apatinib Primary outcome(s): time to progression Study Design: Non randomized control

| 2671010 | ecrin-mdr-crc

Application and evaluation of drug-eluting beads in interventional therapy of liver metastasis in colorectal cancer

Project description:Interventions: Experimental group:DEB-tace;control group:chemotherapy Primary outcome(s): PFS Study Design: Randomized parallel controlled trial

| 2679092 | ecrin-mdr-crc

TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens

Project description:Liver metastasis is the main reason that affects the survival rates of patients with colorectal cancer (CRLM), and is also the main cause of death of those patients. Especially after the failure of first-line or second-line system treatment, the prognosis of those patients is extremely poor, with the median OS of only 3.5 months. Even in combination with molecular targeted drugs such as cetuximab or bevacizumab, the median tumor-free survival period is only 4.8-6.8 months, and OS is only 11-15 months. When they have disease progression, treatment is currently a difficult clinical problem. Regofinib is a new targeted drug for the third-line treatment of advanced colorectal cancer in recent years. However, in the prospective multicenter clinical study, compared with the placebo group, the extended OS is only 1.4 months, which is not so satisfactory. How to improve the survival of these advanced patients with drug resistance is an important clinical problem to be solved urgently. Minimally invasive local treatment may be a promising way to solve this problem. Transcatheter arterial chemoembolization (TACE) and hepatic artery infusion chemotherapy (HAIC) are currently the most widely used methods in clinical practice. In theory, TACE combined with HAIC can control small metastasis and embolic residual lesions. The combination of TACE and HAIC can improve the curative effect. Whether the combination of TACE, HAIC and Regofinib can be expected to achieve the effect of 1+1+1>3 in CRLM patients who have failed the previous second-line chemotherapy remains unknown. Therefore, the purpose of this study is to explore the safety and clinical efficacy of irinotecan-loaded drug-eluting beads-TACE (DEBIRI-TACE) combined with HAIC and Regofinib in the treatment of patients with CRLM who failed standard treatment regimens.

| 108218 | ecrin-mdr-crc

Whole-transcriptome sequencing of hepatocellular carcinoma biopsies (TACE study)

Project description:We performed a transcriptomic analysis of hepatocellular carcinomas (HCCs) and paired non-tumor biopsies to identify predictive biomarkers for response to transarterial chemoembolization (TACE). We identified several transcripts which are predictive of response to TACE.

| EGAS00001005558 | EGA

A Randomized Controlled Trial of Advanced Colorectal Cancer with Fuzheng Jiedu Prescription Combined with Chemotherapy

Project description:Interventions: Experimental group:Fuzheng Jiedu Prescription Combined with Chemotherapy;control group:Chemotherapy Primary outcome(s): PFS Study Design: Parallel

| 2699171 | ecrin-mdr-crc

A multi-center single arm study of FOLFIRI combined with Apatinib on the treatment of non resectable metastatic colorectal cancer

Project description:Interventions: experimental group:FOLFIRI combined with apatinib Primary outcome(s): PFS Study Design: Single arm

| 2676687 | ecrin-mdr-crc